Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...
DexCom (NasdaqGS:DXCM) is upgrading its Stelo glucose monitoring platform with AI driven features that expand its nutrition database and deliver more personalized health insights. The new tools focus ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...
DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results